↓ Skip to main content

Dove Medical Press

Article Metrics

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome

Overview of attention for article published in Clinical Interventions in Aging, June 2012
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter
1 tweeter
wikipedia
1 Wikipedia page

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
31 Mendeley
Title
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
Published in
Clinical Interventions in Aging, June 2012
DOI 10.2147/cia.s24659
Pubmed ID
Authors

Ellen K Ritchie

Abstract

The goals of treating older patients with myelodysplastic syndrome (MDS) are different than for younger patients. Few elderly patients are able to pursue an allogeneic stem cell transplant for potential cure of the disease. The focus for the treatment of older patients with MDS is therefore not curative, but rather alleviation of symptoms, improvement in quality of life, maintenance or improvement of functional status, and continued independent living. Prolongation of survival is only important if functional status and quality of life can be maintained, and there is greater risk of losing these outcomes in elderly patients. Azacitidine is an important drug for the treatment of older patients with MDS. Data from the AZA-001 trial has shown a survival benefit for patients with high-risk disease treated with azacitidine. Importantly, treatment has also been shown to improve quality of life for MDS patients. Subset analysis of the data has shown that the drug can be used safely in even the oldest patients with MDS and is superior to treatment with other established regimens, such as low-dose cytarabine. Given the delay between the initiation of treatment and the clinical response, patients may need aggressive supportive care with antiemetics, prophylactic antibiotics, and transfusions to maintain them through therapy. Azacitidine provides a better quality of response when it is used beyond the first response, so ongoing treatment is generally recommended in responding patients. A new oral preparation of the drug is in development that will make the treatment more feasible and comfortable for elderly patients.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 31 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 23%
Other 5 16%
Student > Master 5 16%
Professor > Associate Professor 4 13%
Student > Doctoral Student 3 10%
Other 4 13%
Unknown 3 10%
Readers by discipline Count As %
Medicine and Dentistry 14 45%
Agricultural and Biological Sciences 4 13%
Social Sciences 3 10%
Pharmacology, Toxicology and Pharmaceutical Science 2 6%
Psychology 2 6%
Other 2 6%
Unknown 4 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 May 2018.
All research outputs
#5,233,559
of 17,359,532 outputs
Outputs from Clinical Interventions in Aging
#574
of 1,598 outputs
Outputs of similar age
#81,869
of 295,368 outputs
Outputs of similar age from Clinical Interventions in Aging
#7
of 20 outputs
Altmetric has tracked 17,359,532 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 1,598 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 295,368 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.